Research record
NTRK fusion-positive melanoma
NTRK fusions are uncommon, but if present they can shift the conversation toward tumor-agnostic targeted therapy or trials.
What this is
NTRK fusions are uncommon, but if present they can shift the conversation toward tumor-agnostic targeted therapy or trials.
Why it may come up
- Confirm whether the report says an NTRK fusion, not just NTRK expression.
- Ask whether a tumor-agnostic drug approval or clinical trial is relevant in the care country.
What not to assume
- Do not assume NTRK is relevant unless a fusion or actionable alteration is documented.
- Availability depends on country, label, and testing confirmation.
- Gene
- NTRK
- Cancer type
- melanoma
- Last checked
- 2026-05-20
What we know
- Confirm whether the report says an NTRK fusion, not just NTRK expression.
- Ask whether a tumor-agnostic drug approval or clinical trial is relevant in the care country.
What is unclear
- Do not assume NTRK is relevant unless a fusion or actionable alteration is documented.
- Availability depends on country, label, and testing confirmation.
Questions to ask
- Which parts of this result are actionable?
- Which parts are mainly useful for trial search?
- Would a melanoma specialty center review change the conversation?